Trial reportNeuroImage. Clinical2026
Functional gradient reorganization and transcriptomic signatures underlying 1 Hz rTMS treatment in first-episode schizophrenia following right orbitofrontal cortex stimulation.
Trial report in NeuroImage. Clinical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe orbitofrontal cortex (OFC) represents a promising yet underexplored neuromodulation target for negative symptoms in schizophrenia, and the macroscale and microscale mechanisms underlying its therapeutic effects remain unclear.
methodsIn a randomized, double-blind, sham-controlled trial, 84 patients with drug-naïve first-episode schizophrenia received consecutive 20 days of active 1-Hz repetitive transcranial magnetic stimulation (rTMS) over the right OFC (n = 45) or sham (n = 39). Resting-state fMRI gradient mapping was integrated with imaging transcriptomics to characterize multiscale neural reorganization and predict treatment response.
resultsActive rTMS was associated with greater improvement in negative symptoms and general psychopathology compared with sham stimulation. Gradient analyses indicated a renormalization of macroscale functional hierarchy, with increased principal gradient scores in transmodal nodes (e.g., right middle occipital gyrus and angular gyri) and decreased scores in salience-related regions (e.g., anterior cingulate cortex). These spatial patterns were coupled to transcriptomic signatures enriched for synaptic plasticity and ion transport, with cell-type enrichment implicating cortical interneurons and oligodendrocytes. In addition, baseline gradient topographies in the right middle occipital gyrus and ventral attention network predicted improvements in negative and general symptoms, respectively.
conclusionsLow-frequency OFC-rTMS was associated with alleviation of negative symptoms in first-episode schizophrenia, alongside a reconfiguration of cortical functional hierarchy. The observed gradient effects were spatially linked to molecular pathways underlying synaptic plasticity and excitation-inhibition regulation, supporting functional gradients as biomarkers for precision neuromodulation in early-stage schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.